Literature DB >> 24022154

Maximizing the commercial value of personalized therapeutics and companion diagnostics.

Cynthia H Zhang1, Y Philip Zhang.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24022154     DOI： 10.1038/nbt.2679

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

Review 1.  Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer.

Authors:  Jan Trøst Jørgensen; Kirsten Vang Nielsen; Bent Ejlertsen
Journal:  Oncologist       Date:  2007-04

Review 2.  Personalized medicine using DNA biomarkers: a review.

Authors:  Andreas Ziegler; Armin Koch; Katja Krockenberger; Anika Grosshennig
Journal:  Hum Genet       Date:  2012-07-01       Impact factor: 4.132
  2 in total
  3 in total

Review 1.  Immuno-Imaging (PET/SPECT)-Quo Vadis?

Authors:  Carsten S Kramer; Antonia Dimitrakopoulou-Strauss
Journal:  Molecules       Date:  2022-05-23       Impact factor: 4.927

2.  Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines.

Authors:  Paul Geeleher; Nancy J Cox; R Stephanie Huang
Journal:  Genome Biol       Date:  2014-03-03       Impact factor: 13.583

3.  Differential Dependency of Human Pancreatic Cancer Cells on Targeting PTEN via PLK 1 Expression.

Authors:  Jungwhoi Lee; Jungsul Lee; Woogwang Sim; Jae-Hoon Kim
Journal:  Cancers (Basel)       Date:  2020-01-23       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.